HOUSTON, Aug. 27, 2020 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers of the brain
and central nervous system, today announces Patrick Wen, M.D., a professor of neurology at
Harvard Medical School and director of
the Center for Neuro-Oncology at Dana-Farber Cancer Institute, has
joined the Company's Science Advisory Board.
"We are excited to add Dr. Wen, a neuro-oncologist with a
passion for and background in investigating cures for deadly brain
cancers, such as glioblastoma, to our Science Advisory Board,"
commented John Climaco, CEO of CNS
Pharmaceuticals. "We believe Dr. Wen's extensive experience in the
field of neuro-oncology will prove invaluable as we continue to
prepare for our upcoming Berubicin clinical trials. The addition of
Dr. Wen strongly complements our strategy to further drive the
development of Berubicin as we look forward to initiating our Phase
I pediatric and Phase II adult studies in Poland and our Phase II trial in the U.S."
Dr. Wen is an accomplished neuro-oncologist with a proven track
record of treating brain tumors and neurologic complications of
cancer. He graduated from the Medical College of St. Bartholomew's
Hospital, University of London,
and completed his internal medicine training at the University of
London postgraduate hospitals.
Subsequently, Dr. Wen completed his neurology residency in the
Harvard-Longwood Neurology Training Program. He is currently a
professor of neurology at Harvard Medical
School and a director of the Center for Neuro-Oncology at
Dana-Farber.
As previously announced, CNS Pharmaceuticals recently engaged
USA-based Pharmaceutics
International, Inc. (Pii) and Italian BSP Pharmaceuticals SpA (BSP)
for the production of the Berubicin drug product. The Company
decided to implement a dual-track drug product manufacturing
strategy to mitigate COVID-19-related risks, diversify its supply
chain, and provide for localized availability of Berubicin. CNS has
completed synthesis of Berubicin active pharmaceutical ingredient
(API) and has shipped API to both manufacturers to prepare an
injectable form of Berubicin for clinical use.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is developing novel treatments for primary and
metastatic cancers of the brain and central nervous system. Its
lead drug candidate, Berubicin, is proposed for the treatment of
glioblastoma multiforme (GBM), an aggressive and incurable form of
brain cancer. CNS holds a worldwide exclusive license to the
Berubicin chemical compound and has acquired all data and know-how
from Reata Pharmaceuticals, Inc. related to a completed Phase 1
trial with Berubicin in GBM, which Reata conducted in 2006. In this
trial, 44% of patients experienced a statistically significant
improvement in progression-free survival. This 44% disease control
rate was based on 11 patients (out of 25 evaluable patients) with
stable disease, plus responders. One patient experienced a durable
complete response and remains cancer-free as of Feb. 20, 2020. By the end of 2020, CNS expects to
commence a Phase 2 clinical trial of Berubicin for the treatment of
GBM in the U.S., while a sub-licensee partner undertakes a Phase 2
trial in adults and a first-ever Phase 1 trial in pediatric GBM
patients in Poland. The Company's second drug candidate,
WP1244, is a novel DNA binding agent that has shown in preclinical
studies that it is 500 times more potent than the chemotherapeutic
agent daunorubicin in inhibiting tumor cell proliferation.
Forward-Looking Statements
Some of the statements in
this press release are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of the Company to initiate
its Phase 2 trial by the end of 2020. These statements relate to
future events, future expectations, plans and prospects. Although
CNS believes the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. CNS has attempted to
identify forward-looking statements by terminology, including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes.
These statements are only predictions and involve known and unknown
risks, uncertainties and other factors, including those discussed
in the Company's SEC filings, including under Item 1A. "Risk
Factors" in the Company's most recently filed Form 10-K, filed with
the Securities and Exchange Commission ("SEC") and updated from
time to time in the Company's Form 10-Q filings and in its other
public filings with the SEC. Any forward-looking statements
contained in this press release speak only as of its date. CNS
undertakes no obligation to update any forward-looking statements
contained in this press release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-appointment-of-dr-patrick-wen-director-of-center-for-neuro-oncology-at-dana-farber-cancer-institute-to-science-advisory-board-301119547.html
SOURCE CNS Pharmaceuticals, Inc.